Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 114

1.

[Adjuvant radiotherapy for bladder cancer in patients with risk of locoregional recurrence: Who, what and how?]

Sargos P, Larré S, Chapet O, Latorzeff I, Fléchon A, Roubaud G, Orré M, Belhomme S, Richaud P.

Cancer Radiother. 2017 Feb 7. pii: S1278-3218(17)30004-5. doi: 10.1016/j.canrad.2016.08.131. [Epub ahead of print] French.

PMID:
28187997
2.

Impact of Primary Metastatic Bone Disease in Germ Cell Tumors: Results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.

Oing C, Oechsle K, Necchi A, Loriot Y, De Giorgi U, Fléchon A, Daugaard G, Fedyanin M, Faré E, Bokemeyer C.

Ann Oncol. 2016 Dec 19. pii: mdw648. [Epub ahead of print]

PMID:
27993806
3.

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann KP, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Gillessen S.

J Clin Oncol. 2017 Jan 10;35(2):194-200.

PMID:
27893332
4.

Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.

Dusaud M, Malavaud B, Bayoud Y, Sebe P, Hoepffner JL, Salomon L, Houlgatte A, Pignot G, Rigaud J, Fléchon A, Pfister C, Rouprêt M, Soulié M, Méjean A, Durand X.

J Surg Oncol. 2016 Dec;114(8):992-996. doi: 10.1002/jso.24464.

PMID:
27859263
5.

[CCAFU french national guidelines 2016-2018 on retroperitoneal sarcoma].

Murez T, Fléchon A, Rocher L, Camparo P, Morel-Journel N, Savoie PH, Ferretti L, Sèbe P, Méjean A, Durand X.

Prog Urol. 2016 Nov;27 Suppl 1:S183-S190. doi: 10.1016/S1166-7087(16)30708-4. French.

PMID:
27846931
6.

[CCAFU french national guidelines 2016-2018 on penile cancer].

Sèbe P, Ferretti L, Savoie PH, Morel-Journel N, Fléchon A, Murez T, Rocher L, Camparo P, Méjean A, Durand X.

Prog Urol. 2016 Nov;27 Suppl 1:S167-S179. doi: 10.1016/S1166-7087(16)30707-2. French.

PMID:
27846930
7.

[CCAFU french national guidelines 2016-2018 on testicular germ cell tumors].

Durand X, Fléchon A, Murez T, Rocher L, Camparo P, Morel-Journel N, Savoie PH, Ferretti L, Sèbe P, Méjean A.

Prog Urol. 2016 Nov;27 Suppl 1:S147-S165. doi: 10.1016/S1166-7087(16)30706-0. French.

PMID:
27846929
8.

Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: The AGEVIM multicenter cohort study.

Laurent M, Brureau L, Demery ME, Fléchon A, Thuaut AL, Carvahlo-Verlinde M, Bastuji-Garin S, Paillaud E, Canoui-Poitrine F, Culine S.

Urol Oncol. 2017 Jan;35(1):34.e9-34.e16. doi: 10.1016/j.urolonc.2016.08.003.

PMID:
27720631
9.

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F.

Cancer Treat Rev. 2016 Sep 10. pii: S0305-7372(16)30088-3. doi: 10.1016/j.ctrv.2016.09.008. [Epub ahead of print] Review.

PMID:
27665366
10.

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.

de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R.

JAMA Oncol. 2017 Jan 1;3(1):68-75. doi: 10.1001/jamaoncol.2016.3000.

PMID:
27560549
12.

Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).

De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl WC, Retz MM, Vaissière N, Culine S.

Ann Oncol. 2016 Mar;27(3):449-54. doi: 10.1093/annonc/mdv609.

13.

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party.

Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F.

Bone Marrow Transplant. 2016 Mar;51(3):384-90. doi: 10.1038/bmt.2015.300.

PMID:
26642334
14.

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients.

Roubaud G, Brouste V, Beuzeboc P, Fléchon A, Tosi D, Lavau-Denes S, Chevreau C, Culine S, Oudard S, Quivy A, Pourquier P, Houédé N.

J Negat Results Biomed. 2015 Nov 10;14:18. doi: 10.1186/s12952-015-0037-5.

15.

Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique.

Murez T, Durand X, Rivoire M, Fournier G, Dariane C, Rouprêt M, Lugagne J, Bosset P, Pignot G, Hetet J, Rigaud J, Safsaf R, Pfister C, Daste A, Sèbe P, Malavaud B, Bossavy J, Houlgatte A, Avances C, Camparo P, Flechon A, Culine S, Iborra F, Mottet N, Coloby P, Soulié M.

Prog Urol. 2014 Nov;24(13):865. doi: 10.1016/j.purol.2014.08.180. French. No abstract available.

PMID:
26461706
16.

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A, Boyle H, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Sava T, Winquist EW, De Giorgi U, Aparicio J, Sweeney CJ, Cohn Cedermark G, Beyer J, Powles T.

J Clin Oncol. 2016 Feb 1;34(4):345-51. doi: 10.1200/JCO.2015.62.7000.

17.

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY.

Oncotarget. 2015 Sep 22;6(28):26388-99. doi: 10.18632/oncotarget.4557.

18.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X.

PMID:
26028518
19.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.

Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, Delva R, Fléchon A, Latorzeff I, Ferrero JM, Oudard S, Tartas S, Laguerre B, Topart D, Roubaud G, Agherbi H, Rebillard X, Azria D.

BMC Cancer. 2015 Apr 4;15:222. doi: 10.1186/s12885-015-1257-2.

20.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K.

Lancet Oncol. 2015 Apr;16(4):417-25. doi: 10.1016/S1470-2045(15)70025-2.

PMID:
25743937
Items per page

Supplemental Content

Loading ...
Support Center